Stock of the Day

August 8, 2024

BioXcel Therapeutics (BTAI)

$0.88
-$0.00 (-0.5%)
Market Cap: $27.40M

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Today's Trend

BioXcel Therapeutics (NASDAQ: BTAI) shares moved higher today after the company reported positive at-home Phase 3 safety trial data for its sublingual film therapy, BXCL501, and outlined plans for a supplemental NDA submission. Volume spiked following a brief trading halt on pending news, while analysts remain divided on the stock’s valuation.

  • Clinical trials: BXCL501 met its primary endpoint for tolerability in the SERENITY At-Home pivotal Phase 3 safety trial of its sublingual film for at-home agitation treatment, with no discontinuations due to tolerability and consistent safety across repeat dosing. UPDATE Press Release
  • Regulatory outlook: BioXcel plans to submit a supplemental New Drug Application (sNDA) in Q1 2026 to expand outpatient use of IGALMI® (BXCL501) based on positive feedback from the FDA and successful at-home study results. Reuters
  • Retail investor interest: Coverage by MSN and Business Insider highlighted strong tolerability in bipolar and schizophrenia trials and anticipated a “retail frenzy,” driving trading volume. MSN Article
  • Analyst upshot: HC Wainwright reiterated a “Buy” rating with a $10 price target, implying roughly 144% upside from current levels. Benzinga
  • Trading halt: NASDAQ briefly halted BTAI trading early Wednesday for pending news, lifting the restriction once the trial update was released.
  • Topline announcement: BioXcel flagged its upcoming SERENITY At-Home trial results in advance via Business Insider, setting the stage for today’s detailed data release. Business Insider
  • Analyst downgrade: Zacks Research cut its rating from “Strong-Buy” to “Hold,” citing valuation and near-term approval uncertainties. Zacks.com
← Previous Stock of the DayNext Stock of the Day →